Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals

NCT02471430 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02471430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02471430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2016
Completion date
December 31, 2023
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection